Sodium glucose co-transporter 2-inhibitors clinical and left ventricular function outcomes in post infarction patients
Tanta Medical Journal · 2026-07 · 54 (3) · 390-399
DOI: 10.4103/tmj.tmj_27_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tanta Medical Journal, online erschienen am 24.07.2026. Verfasst von Asmaa A.H. Mohamed und 3 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Worldwide, acute myocardial infarction (AMI) is the primary reason for morbidity and mortality. Despite developments in medical therapy and revascularization methods, patients with AMI remain at risk for serious cardiovascular events. Sodium–glucose cotransporter type 2 inhibitors (SGLT2-I) has offered promise toward improving cardiovascular outcomes in patients with heart failure, irrespective of their diabetic status or ejection fraction.
Aim
To study the impact of SGLT2-I on clinical outcomes and left ventricular functions in patients after AMI. Patients and methods Eighty patients with newly diagnosed first AMI enrolled from April 2023 to April 2024. SGLT2-I users: 40 patients received AMI conventional management in addition to one of the available SGLT2-I (empagliflozin or dapagliflozin). Non-SGLT2-I users: 40 patients received AMI conventional management without SGLT2-I. Baseline and 6-month clinical, laboratory, and echocardiographic examination were performed.
Results
After 6 months, SGLT2-I users showed better clinical outcomes, improved heart failure symptoms, fewer adverse events, and better control of systolic blood pressure, hemoglobin A1C, and serum creatinine. Echocardiographic parameters showed significant improvement; left atrial volume index decreased from 35.1 ± 8.0 to 27.4 ± 8.4, E/é decreased from 14.2 ± 2.6 to 10.2 ± 2.6 together with considerable improvement in the degree of functional mitral incompetence, P =0.013.
Conclusion
Adding SGLT2-I to standard AMI therapy leads to improved clinical outcomes, and reduced heart failure and ischemia symptoms with better control of clinical and laboratory variables. Furthermore, there is a favorable impact on LV reverse remodeling parameters, improving ejection fraction, peak early diastolic mitral flow velocity/pulsed-wave tissue Doppler-derived early diastolic velocity ratio, left atrial volume index, the degree of functional mitral incompetence compared with nonusers.
Zitieren
APA
Mohamed, A. A., Badr, S. F., Hussien, M. N., & Saied, S. A. E. (2026). Sodium glucose co-transporter 2-inhibitors clinical and left ventricular function outcomes in post infarction patients. Tanta Medical Journal, 54(3), 390-399. https://doi.org/10.4103/tmj.tmj_27_25
Vancouver
Mohamed AA, Badr SF, Hussien MN, Saied SAE. Sodium glucose co-transporter 2-inhibitors clinical and left ventricular function outcomes in post infarction patients. Tanta Medical Journal. 2026;54(3):390-399. doi:10.4103/tmj.tmj_27_25
BibTeX
@article{Mohamed2026,
author = {Mohamed, Asmaa A.H. and Badr, Seham F. and Hussien, Mohamed N. and Saied, Shaimaa A.B. El},
title = {Sodium glucose co-transporter 2-inhibitors clinical and left ventricular function outcomes in post infarction patients},
journal = {Tanta Medical Journal},
year = {2026},
volume = {54},
number = {3},
pages = {390--399},
doi = {10.4103/tmj.tmj_27_25}
}
EUVIMED